Rockwell MedicaL - RMTI
Rockwell Medical RMTI has just completed a bottom bowl that started 11 months ago. The first Qtr. 2024 was the first profit improvement and the chart display strength with that Quarterly report.
The MACD bottomed in August 2023 and has risen and continues to send strength sikgnals.
The new management has improved sales and forecasted sales of $90+ M for the 2024 which would be a 12% improvements. The healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024.
The chart action indicates that this second quarter report will exceed expectations and street estimates believe the stock could gain substantially over the near term. I forecast the stock price will double in 2024 to $4 per share.
The MACD bottomed in August 2023 and has risen and continues to send strength sikgnals.
The new management has improved sales and forecasted sales of $90+ M for the 2024 which would be a 12% improvements. The healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024.
The chart action indicates that this second quarter report will exceed expectations and street estimates believe the stock could gain substantially over the near term. I forecast the stock price will double in 2024 to $4 per share.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.